Optimizing mesenchymal stem cell-based therapeutics

Current Opinion in Biotechnology

Volumn 20, Issue 5, 2009, Pages 531-536

  Wagner, Joseph ^a   Kean, Thomas ^b   Young, Randell ^a   Dennis, James E ^b   Caplan, Arnold I ^b  

^a Cell Targeting Inc   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; CLINICAL TRIAL; CLINICAL UTILITY; COMMERCIAL IMPLEMENTATION; CYTOKINES; IN-VITRO; MESENCHYMAL STEM CELL; OVER-EXPRESSION; TARGET TISSUES;

BINDING ENERGY; BINDING SITES; CELL CULTURE; CELLS; FLOWCHARTING;

LIGANDS;

BINDING SITE; BIOTECHNOLOGICAL PROCEDURES; BIOTECHNOLOGICAL PRODUCTION; CELL HOMING; CELL MIGRATION; CELL TRANSPORT; CULTURE TECHNIQUE; GENE OVEREXPRESSION; GENETIC MANIPULATION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENICS;

ANIMALS; CELL MOVEMENT; GENE TRANSFER TECHNIQUES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; ORGAN SPECIFICITY;

ANIMALIA;

EID: 70449629693     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2009.08.009     Document Type: Review

References (55)

1. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 9624 (2008) 1579-1586. The use of MSCs for immunomodulatory treatment of graft-versus-host disease represents one of the first clinical studies utilizing the trophic aspects of these cells; this report describes significant benefit of MSC therapy in this indication.
2. Ringdén O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lönnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 10 (2006) 1390-1397
3. Kharaziha P., Hellström P.M., Noorinayer B., Farzaneh F., Aghajani K., Jafari F., Telkabadi M., Atashi A., Honardoost M., Zali M.R., and Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol (2009) Published ahead of print, May 16
4. Vojtassák J., Danisovic L., Kubes M., Bakos D., Jarábek L., Ulicná M., and Blasko M. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett 2 (2006) 134-137
5. Falanga V., Iwamoto S., Chartier M., Yufit T., Butmarc J., Kouttab N., Shrayer D., and Carson P. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 6 (2007) 1299-1312
6. Lee P.H., Kim J.W., Bang O.Y., Ahn Y.H., Joo I.S., and Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 5 (2008) 723-730
7. Macmillan M.L., Blazar B.R., DeFor T.E., and Wagner J.E. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 6 (2009) 447-454
8. Thomas R.J., Chandra A., Liu Y., Hourd P.C., Conway P.P., and Williams D.J. Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology 1 (2007) 31-39
9. Thomas R.J., Hourd P.C., and Williams D.J. Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. J Biotechnol 3-4 (2008) 148-155
10. Brooke G., Rossetti T., Pelekanos R., Ilic N., Murray P., Hancock S., Antonenas V., Huang G., Gottlieb D., Bradstock K., and Atkinson K. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol 4 (2009) 571-579
11. Dennis J.E., Esterly K., Awadallah A., Parrish C.R., Poynter G.M., and Goltry K.L. Clinical-scale expansion of a mixed population of bone-marrow-derived stem and progenitor cells for potential use in bone-tissue regeneration. Stem Cells 10 (2007) 2575-2582
12. Gastens M.H., Goltry K., Prohaska W., Tschöpe D., Stratmann B., Lammers D., Kirana S., Götting C., and Kleesiek K. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant 16 (2007) 685-696
13. Caplan A.I., and Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 5 (2006) 1076-1084
14. Lu Z., Hu X., Zhu C., Wang D., Zheng X., and Liu Q. Overexpression of CNTF in mesenchymal stem cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice. J Neuroimmunol 1 (2009) 58-69
15. Suzuki M., McHugh J., Tork C., Shelley B., Hayes A., Bellantuono I., Aebischer P., and Svendsen C.N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 12 (2008) 2002-2010
16. Kanki-Horimoto S., Horimoto H., Mieno S., Kishida K., Watanabe F., Furuya E., and Katsumata T. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114 (2006) 181-185
17. Ishii M., Numaguchi Y., Okumura K., Kubota R., Ma X., Murakami R., Naruse K., and Murohara T. Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. Atherosclerosis (2009) Published online April 3
18. Haider H.K., Jiang S., Idris N.M., and Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 11 (2008) 1300-1308
19. Li W., Ma N., Ong L.L., Nesselmann C., Klopsch C., Ladilov Y., Furlani D., Piechaczek C., Moebius J.M., Lützow K., et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 8 (2007) 2118-2127
20. Chang W., Song B.W., Lim S., Song H., Shim C.Y., Cha M.J., Ahn D.H., Jung Y.G., Lee D.H., Chung J.H., et al. Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 9 (2009) 2283-2292
21. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., Mu H., Melo L.G., Pratt R.E., Ingwall J.S., and Dzau V.J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 6 (2006) 661-669
22. Gnecchi M., He H., Melo L.G., Noiseaux N., Morello F., de Boer R.A., Zhang L., Pratt R.E., Dzau V.J., and Ingwall J.S. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 4 (2009) 971-979
23. Noiseux N., Gnecchi M., Lopez-Ilasaca M., Zhang L., Solomon S.D., Deb A., Dzau V.J., and Pratt R.E. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 6 (2006) 840-850
24. Lu G., Haider H.K., Jiang S., and Ashraf M. Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin-43. Circulation 19 (2009) 2587-2596
25. Hahn J.Y., Cho H.J., Kang H.J., Kim T.S., Kim M.H., Chung J.H., Bae J.W., Oh B.H., Park Y.B., and Kim H.S. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 9 (2008) 933-943
26. Rosová I., Dao M., Capoccia B., Link D., and Nolta J.A. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 8 (2008) 2173-2182
27. Wisel S., Khan M., Kuppusamy M.L., Mohan I.K., Chacko S.M., Rivera B.K., Sun B.C., Hideg K., and Kuppusamy P. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2 (2009) 543-550
28. Tang Y.L., Zhu W., Cheng M., Chen L., Zhang J., Sun T., Kishore R., Phillips M.I., Losordo D.W., and Qin G. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 10 (2009) 1209-1216
29. Fischer U.M., Harting M.T., Jimenez F., Monzon-Posadas W.O., Xue H., Savitz S.I., Laine G.A., and Cox C.S. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 5 (2009) 683-692
30. Harting M.T., Jimenez F., Xue H., Fischer U.M., Baumgartner J., Dash P.K., and Cox C.S. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 6 (2009) 1189-1197
31. Karp J.M., and Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 3 (2009) 206-216. This detailed review presents a broad survey of current MSC tracking methodologies and makes a compelling case for standardization in quantitative and qualitative methodologies before conclusions regarding latent homing of MSCs are made.
32. Yamaguchi J., Kusano K.F., Masuo O., Kawamoto A., Silver M., Murasawa S., Bosch-Marce M., Masuda H., Losordo D.W., Isner J.M., and Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 9 (2003) 1322-1328
33. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., Rovner A., Ellis S.G., Thomas J.D., DiCorleto P.E., Topol E.J., and Penn M.S. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 9385 (2003) 697-703
34. Penn M.S. Importance of the SDF-1:CXCR4 axis in myocardial repair. Circ Res 10 (2009) 1133-1135. This recent review presents a concise summary of the current understanding of SDF-1-mediated MSC homing by a leader in the field.
35. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., Koc O.N., and Penn M.S. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 12 (2007) 3197-3207
36. Zhao T., Zhang D., Millard R.W., Ashraf M., and Wang Y. Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1alpha delivery and endogenous cytokine signaling. Am J Physiol Heart Circ Physiol 4 (2009) 976-986
37. Zhang D., Fan G.C., Zhou X., Zhao T., Pasha Z., Xu M., Zhu Y., Ashraf M., and Wang Y. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 2 (2008) 281-292
38. Bhakta S., Hong P., and Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. Cardiovasc Revasc Med 1 (2006) 19-24
39. Cheng Z., Ou L., Zhou X., Li F., Jia X., Zhang Y., Liu X., Li Y., Ward C.A., Melo L.G., and Kong D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 3 (2008) 571-579
40. Steingen C., Brenig F., Baumgartner L., Schmidt J., Schmidt A., and Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol 6 (2008) 1072-1084
41. Ries C., Egea V., Karow M., Kolb H., Jochum M., and Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 9 (2007) 4055-4063
42. De Becker A., Van Hummelen P., Bakkus M., Vande Broek I., De Wever J., De Waele M., and Van Riet I. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 4 (2007) 440-449
43. Sackstein R., Merzaban J.S., Cain D.W., Dagia N.M., Spencer J.A., Lin C.P., and Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2 (2008) 181-187. One of the first studies attempting to modify MSC homing ability without using transgenic methodologies; instead, the authors chemically modified an endogenous surface molecule to successfully impart marrow homing properties on MSCs.
44. Kumar S., and Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J 14 (2007) 3917-3927
45. Lee R.J., Fang Q., Davol P.A., Gu Y., Sievers R.E., Grabert R.C., Gall J.M., Tsang E., Yee M.S., Fok H., et al. Antibody targeting of stem cells to infarcted myocardium. Stem Cells 3 (2007) 712-717
46. Lum L.G., Fok H., Sievers R., Abedi M., Quesenberry P.J., and Lee R.J. Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium. Blood Cells Mol Dis 32 (2004) 82-87
47. Dennis J.E., Cohen N., Goldberg V.M., and Caplan A.I. Targeted delivery of progenitor cells for cartilage repair. J Orthop Res 4 (2004) 735-741
48. Ko I.K., Kean T.J., and Dennis J.E. Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials 22 (2009) 3702-3710
49. Sarkar D., Vemula P.K., Teo G.S., Spelke D., Karnik R., Wee le Y., and Karp J.M. Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjug Chem 11 (2008) 2105-2109
50. Ruoslahti E., and Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 18 (2000) 813-827
51. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2 (2002) 83-90
52. Zhang L., Hoffman J.A., and Ruoslahti E. Molecular profiling of heart endothelial cells. Circulation 112 (2005) 1601-1611
53. Pilch J., Brown D.M., Komatsu M., Jarvinen T., Yang M., Peters D., Hoffman R.M., and Ruoslahti E. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A 103 (2006) 2800-2804
54. Jarvinen T., and Ruoslahti E. Molecular changes in the vasculature of injured tissues. Am J Pathol 171 (2007) 702-711
55. Fogal V., Zhang L., and Ruoslahti E. Mitochondrial/cell surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68 (2008) 7210-7218